Optimizing outcomes in HER2-positive breast cancer: the molecular rationale

Oncology (Williston Park). 2005 Nov;19(13 Suppl 5):4.
No abstract available

MeSH terms

  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Chemotherapy, Adjuvant
  • Female
  • Humans
  • Receptor, ErbB-2 / antagonists & inhibitors*
  • Receptor, ErbB-2 / metabolism*

Substances

  • Antineoplastic Agents
  • Receptor, ErbB-2